HK1198744A1 - Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts - Google Patents

Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts

Info

Publication number
HK1198744A1
HK1198744A1 HK14112247.0A HK14112247A HK1198744A1 HK 1198744 A1 HK1198744 A1 HK 1198744A1 HK 14112247 A HK14112247 A HK 14112247A HK 1198744 A1 HK1198744 A1 HK 1198744A1
Authority
HK
Hong Kong
Prior art keywords
opiate
morphine
antagonist
prevention
treatment
Prior art date
Application number
HK14112247.0A
Other languages
English (en)
Chinese (zh)
Inventor
．赫曼
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36675685&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1198744(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of HK1198744A1 publication Critical patent/HK1198744A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14112247.0A 2006-01-19 2014-12-04 Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts HK1198744A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06100578A EP1810678A1 (de) 2006-01-19 2006-01-19 Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution

Publications (1)

Publication Number Publication Date
HK1198744A1 true HK1198744A1 (en) 2015-06-05

Family

ID=36675685

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112247.0A HK1198744A1 (en) 2006-01-19 2014-12-04 Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts

Country Status (19)

Country Link
US (2) US20100221339A1 (xx)
EP (2) EP1810678A1 (xx)
CN (2) CN101370503A (xx)
AT (1) ATE465735T1 (xx)
AU (1) AU2007206914B2 (xx)
CA (1) CA2637458C (xx)
CY (1) CY1110152T1 (xx)
DE (1) DE502007003589D1 (xx)
DK (1) DK1976524T4 (xx)
EA (1) EA014539B1 (xx)
ES (1) ES2345286T5 (xx)
HK (1) HK1198744A1 (xx)
HR (1) HRP20100373T4 (xx)
PL (1) PL1976524T5 (xx)
PT (1) PT1976524E (xx)
RS (1) RS51388B2 (xx)
SI (1) SI1976524T1 (xx)
UA (1) UA92380C2 (xx)
WO (1) WO2007082935A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007024428A1 (de) 2007-05-25 2008-11-27 Hermann, Holger Lars, Dr. med. Verwendung von Naloxon als Abususschutz bei Nicht-Opioiden und Nicht-Opiaten
WO2010121600A2 (de) 2009-04-22 2010-10-28 Lars Holger Hermann Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten
JP2012087101A (ja) 2010-10-21 2012-05-10 Holger Hermann Lars オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
CN103695497B (zh) * 2013-12-20 2014-09-17 奇方(天津)医药科技有限公司 纳洛酮的酶法制备及其药物组合物
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
WO2015089530A1 (de) 2013-12-20 2015-06-25 G.L. PHARMA GmbH Orale darreichungsform mit verzögerter freisetzung enthaltend morphin und naloxon
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1390772A (en) * 1971-05-07 1975-04-16 Endo Lab Oral narcotic composition
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5580876A (en) † 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
SE9301057L (sv) 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
DE4325465B4 (de) * 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
AT403988B (de) 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
WO1997033566A2 (en) * 1996-03-12 1997-09-18 Alza Corporation Composition and dosage form comprising opioid antagonist
EP0914823B1 (de) 1997-11-06 2004-12-08 Lannacher Heilmittel Ges.m.b.H. Orale Retard-Präparation enthaltend Tramadol sowie Verfahren zu ihrer Herstellung
KR100417490B1 (ko) * 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 오피오이드 제형의 남용을 방지하는 방법
DK1685839T3 (da) * 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
AU2406299A (en) 1998-02-12 1999-08-30 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
EP2092936B1 (en) † 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
CA2446550C (en) † 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
US20030044458A1 (en) † 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
EP2308475A1 (en) 2002-04-05 2011-04-13 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
US20050191244A1 (en) * 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
AT503858B1 (de) 2003-06-05 2008-08-15 Lannacher Heilmittel Verfahren zur herstellung einer festen oralen pharmazeutischen zusammensetzung, enthaltend ein jodsalz
WO2006079550A2 (en) 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
FR2889810A1 (fr) * 2005-05-24 2007-02-23 Flamel Technologies Sa Forme medicamenteuse orale, microparticulaire, anti-mesurage
GB2471801B (en) 2006-05-25 2011-02-16 Alpharma Process useful in the preparation of morphine antagonists
PL2034975T3 (pl) 2006-06-19 2012-09-28 Alpharma Pharmaceuticals Llc Kompozycje farmaceutyczne

Also Published As

Publication number Publication date
CA2637458C (en) 2015-03-10
HRP20100373T4 (hr) 2016-12-16
US20100221339A1 (en) 2010-09-02
EP1810678A1 (de) 2007-07-25
PL1976524T3 (pl) 2010-10-29
PT1976524E (pt) 2010-07-05
ES2345286T5 (es) 2017-04-25
EP1976524A1 (de) 2008-10-08
CN103893179A (zh) 2014-07-02
ES2345286T3 (es) 2010-09-20
RS51388B (en) 2011-02-28
DE502007003589D1 (de) 2010-06-10
US10507205B2 (en) 2019-12-17
DK1976524T4 (en) 2016-12-05
CN101370503A (zh) 2009-02-18
ATE465735T1 (de) 2010-05-15
UA92380C2 (ru) 2010-10-25
HRP20100373T1 (en) 2010-08-31
RS51388B2 (sr) 2018-02-28
US20170136005A1 (en) 2017-05-18
WO2007082935A1 (de) 2007-07-26
AU2007206914A1 (en) 2007-07-26
SI1976524T1 (sl) 2010-08-31
CA2637458A1 (en) 2007-07-26
AU2007206914B2 (en) 2012-08-23
EP1976524B1 (de) 2010-04-28
EP1976524B2 (de) 2016-08-10
DK1976524T3 (da) 2010-08-09
EA200870182A1 (ru) 2009-02-27
EA014539B1 (ru) 2010-12-30
PL1976524T5 (pl) 2017-12-29
CY1110152T1 (el) 2015-01-14

Similar Documents

Publication Publication Date Title
HK1198744A1 (en) Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts
Reimer et al. Meeting the challenges of opioid-induced constipation in chronic pain management–a novel approach
Lugo et al. The pharmacokinetics of oxycodone
IL221795B (en) Use of a pharmaceutical preparation of methylnaltrexone or a salt thereof for the preparation of a medicine for the treatment of side effects of treatment with opiates
TWI365880B (en) Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
US20210299139A1 (en) Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
HK1104471A1 (en) Opioids for the treatment of the chronic obstructive pulmonary disease (copd)
IL179896A (en) Opioid with a delayed oral dosage form containing a mixture of opioid agonist and antagonist for use in the treatment of nervous leg syndrome
RS52831B (en) THIN BUPRENORPHINE TILES FOR DRUG REPLACEMENT THERAPY
MY161079A (en) Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
WO2005107726A3 (en) Method for the treatment of back pain
EA200870449A1 (ru) Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами
GB0315861D0 (en) Improvements in pharmaceutical compositions for treatment of drug abuse
HK1139871A1 (en) Improvements in and relating to medicinal compositions
GEP20084569B (en) Pharmaceutical composition for treating atherosclerosis, dyslipidemias and related conditions and use thereof for treating said diseases
UA109781C2 (uk) Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
Campbell et al. Antinociceptive effects of alcohol and nicotine: involvement of the opioid system
ZA200610770B (en) Dosage form for delivery of multiple drug forms
JP7244992B2 (ja) オピオイドとｎ－アシルエタノールアミンの組み合わせ
US20030199496A1 (en) Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use
Sharma et al. Fentanyl-A Potent Opioid Analgesic: A Review
WO2006041769A3 (en) Methods for the treatment of substance abuse and addiction
KR20200022026A (ko) 치료 방법 및 이의 약형